The widespread use of powerful, relatively new weight-loss drugs in the United States could boost gross domestic product by 1% in the coming years as lower obesity-related health complications are likely to boost workplace efficiency, according to financial giant Goldman Sachs.
Some analysts have predicted the market for weight-loss drugs could reach $100bn a year by the end of the decade, with Ozempic maker Novo Nordisk and Mounjaro producer Eli Lilly leading the race.
